SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 15:41:09 2024-06-14 EDT | ||
| 0.011 EUR | 0.00% |
|
| Current month | +37.50% | ||
| 1 month | -26.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 0.011 | 0.00% |
| 24-06-13 | 0.011 | -8.33% |
| 24-06-12 | 0.012 | +9.09% |
| 24-06-11 | 0.011 | +37.50% |
| 24-06-10 | 0.008 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU2KKY |
| ISIN | DE000SU2KKY7 |
| Date issued | 2023-11-21 |
| Strike | 62 $ |
| Maturity | 2024-09-20 (97 Days) |
| Parity | 10 : 1 |
| Emission price | 0.098 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.15 € |
|---|---|
| Lowest since issue | 0.004 € |
| Spread | 0.01 € |
| Spread % | 47.62% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Warrants
- Warrant
